Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.

Publication ,  Journal Article
Vassel, F-M; Bian, K; Walker, GC; Hemann, MT
Published in: Proc Natl Acad Sci U S A
November 17, 2020

Cisplatin is a standard of care for lung cancer, yet platinum therapy rarely results in substantial tumor regression or a dramatic extension in patient survival. Here, we examined whether targeting Rev7 (also referred to as Mad2B, Mad2L2, and FANCV), a component of the translesion synthesis (TLS) machinery, could potentiate the action of cisplatin in non-small cell lung cancer (NSCLC) treatment. Rev7 loss led to an enhanced tumor cell sensitivity to cisplatin and dramatically improved chemotherapeutic response in a highly drug-resistant mouse model of NSCLC. While cisplatin monotherapy resulted in tumor cell apoptosis, Rev7 deletion promoted a cisplatin-induced senescence phenotype. Moreover, Rev7 deficiency promoted greater cisplatin sensitivity than that previously shown following targeting of other Pol ζ-proteins, suggesting that Pol ζ-dependent and -independent roles of Rev7 are relevant to cisplatin response. Thus, targeting Rev7 may represent a unique strategy for altering and enhancing chemotherapeutic response.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Proc Natl Acad Sci U S A

DOI

EISSN

1091-6490

Publication Date

November 17, 2020

Volume

117

Issue

46

Start / End Page

28922 / 28924

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Mutagenesis
  • Mice
  • Mad2 Proteins
  • Lung Neoplasms
  • Humans
  • Drug Resistance, Neoplasm
  • DNA-Directed DNA Polymerase
  • DNA-Binding Proteins
  • DNA Repair
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vassel, F.-M., Bian, K., Walker, G. C., & Hemann, M. T. (2020). Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Proc Natl Acad Sci U S A, 117(46), 28922–28924. https://doi.org/10.1073/pnas.2016067117
Vassel, Faye-Marie, Ke Bian, Graham C. Walker, and Michael T. Hemann. “Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.Proc Natl Acad Sci U S A 117, no. 46 (November 17, 2020): 28922–24. https://doi.org/10.1073/pnas.2016067117.
Vassel F-M, Bian K, Walker GC, Hemann MT. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28922–4.
Vassel, Faye-Marie, et al. “Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.Proc Natl Acad Sci U S A, vol. 117, no. 46, Nov. 2020, pp. 28922–24. Pubmed, doi:10.1073/pnas.2016067117.
Vassel F-M, Bian K, Walker GC, Hemann MT. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28922–28924.
Journal cover image

Published In

Proc Natl Acad Sci U S A

DOI

EISSN

1091-6490

Publication Date

November 17, 2020

Volume

117

Issue

46

Start / End Page

28922 / 28924

Location

United States

Related Subject Headings

  • Tumor Cells, Cultured
  • Mutagenesis
  • Mice
  • Mad2 Proteins
  • Lung Neoplasms
  • Humans
  • Drug Resistance, Neoplasm
  • DNA-Directed DNA Polymerase
  • DNA-Binding Proteins
  • DNA Repair